✓After hours - Last update: Oct 13, 2026, 10:08 AM ET
🏆Material / Earnings✓High confidence
Source: earnings_events
Changes History →Market closed · After hours · 5:47 PM ET
Last update: Oct 13, 2026, 5:15 PM ETMarket closed·84 changes confirmed today
Track the stock moves that actually matter.
BestStocks detects meaningful changes across price, volume, earnings, filings, valuation, analyst revisions, and risk signals — and shows you the evidence behind each one.
1,000 equities monitored14 signal typesCross-checked against SEC EDGARMedian detection lag ~41s
Investment research built around change detection.
Showing:
BestStocks identifies what changed across companies and sectors, explains why it matters, and helps investors spot opportunities worth investigating.
✓After hours - Last update: Oct 13, 2026, 10:08 AM ET
🏆Material / Earnings✓High confidence
What changed: UnitedHealth Group Incorporated (UNH) reported EPS of $4.69 vs. consensus estimate of $4.14, beating expectations by 13.3%.
Source: earnings_events
Changes History →What's next
What to watch
UNH earnings announcement on 2026-10-27; consensus expects EPS of $4.03.
✓After hours - Last update: Oct 13, 2026, 4:44 PM ET
⚡Material / Earnings✓High confidence
What changed: Core Scientific, Inc. (CORZ) moved +5.87% from $14.57 to $15.43 on October 13, 2026. We checked news, earnings, analyst updates, filings, and corporate actions. A comparison article positioning CORZ against WhiteFiber across valuation, risk, earnings, dividends, and analyst ratings appeared in search results and was cited by Google's AI Overview in connection with the move.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
CORZ earnings announcement on October 23, 2026 (date not yet confirmed).
✓After hours - Last update: Oct 13, 2026, 4:44 PM ET
🛡Material / Earnings✓High confidence
What changed: Vaxcyte, Inc. (PCVX) moved -5.01% from $70.28 to $66.76 on 2026-10-13 following the company's completion of a $1.15 billion public offering of common stock, pre-funded warrants, and convertible senior notes (including $575 million in convertible notes at 1.50% due 2032). The decline represents profit-taking after a 37% rally the prior week triggered by positive Phase 3 data for VAX-31, a 31-valent pneumococcal conjugate vaccine candidate.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
PCVX earnings scheduled for 2026-11-03 with consensus EPS estimate of -$2.11.
✓After hours - Last update: Oct 13, 2026, 4:43 PM ET
🛡Material / Earnings✓High confidence
What changed: Protagonist Therapeutics, Inc. (PTGX) moved -5.14% from $146.00 to $138.49 on 2026-10-13. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average at 1.2x, indicating the decline occurred without unusual trading activity.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Protagonist Therapeutics earnings report expected 2026-11-05.
✓After hours - Last update: Oct 13, 2026, 4:39 PM ET
⚡Material / Earnings✓High confidence
What changed: CDW Corporation (CDW) moved +5.55% from $143.98 to $151.97 on 2026-10-13. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.9x the 5-day average, suggesting modest institutional participation in the move.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
CDW earnings on 2026-11-03 (date not yet confirmed); monitor for EPS surprise relative to the $2.98 consensus estimate.
✓After hours - Last update: Oct 13, 2026, 4:39 PM ET
⚡Material / Earnings✓High confidence
What changed: SiTime Corporation (SITM) moved +5.01% from $552.00 to $579.66 on 2026-10-13, bouncing back after a sharp 6.9% drop the prior session. The rebound was driven by dip-buying at lower levels following the October 12 selloff, which had been triggered by broader tech and semiconductor volatility tied to AI bubble concerns and recent analyst downgrades.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Q3 2026 earnings report on 2026-11-04 against consensus EPS estimate of $3.61.
✓After hours - Last update: Oct 13, 2026, 4:39 PM ET
⚡Material / Earnings✓High confidence
What changed: Vicor Corporation (VICR) moved +7.69% from $248.15 to $267.24 on October 13, 2026, driven by pre-earnings momentum ahead of Q3 results scheduled for October 20. The move followed management's late-September guidance raise, which doubled Q3 sequential growth outlook to over 20%, and comes amid investor positioning around strong anticipated demand for the company's power modules in AI data centers.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Vicor reports Q3 2026 earnings on October 20, 2026, with consensus EPS estimate at $1.32.
✓After hours - Last update: Oct 13, 2026, 4:38 PM ET
⚡Material / Earnings✓High confidence
What changed: Oracle Corporation (ORCL) moved +5.36% from $135.91 to $143.20 on 2026-10-13. News highlighted Oracle's expansion of cloud infrastructure and application services targeting large enterprises and government agencies, alongside a board member's $3.48 million stock purchase. The company previously reported 30% revenue growth with 60% cloud expansion, though bookings declined and growth normalized.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
ORCL earnings are scheduled for 2026-12-09 with consensus EPS estimate of $1.88.
✓After hours - Last update: Oct 13, 2026, 4:38 PM ET
⚡Material / Earnings✓High confidence
What changed: Vistra Corp. (VST) moved +5.77% from $153.51 to $162.36 on 2026-10-13. No company-specific catalyst was identified. CFO Kristopher Moldovan sold 20,000 shares at $165 each under a pre-planned arrangement, and the move occurred on light volume (48% of the 5-day average).
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
VST earnings scheduled for 2026-11-05 (consensus EPS estimate $2.89).
✓After hours - Last update: Oct 13, 2026, 4:38 PM ET
⚡Material / Earnings✓High confidence
What changed: Astera Labs, Inc. (ALAB) moved +5.20% from $309.32 to $325.41 on 2026-10-13. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move occurred on below-average volume (0.6x the 5-day average).
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor ALAB's earnings announcement on 2026-11-03 for actual results against the $1.19 EPS consensus.
✓After hours - Last update: Oct 13, 2026, 4:38 PM ET
⚡Material / Earnings✓High confidence
What changed: Marvell Technology (MRVL) moved +6.00% from $253.53 to $268.73 on October 13, 2026, following PropNotes' upgrade from Hold to Buy and a wave of analyst price-target hikes. BMO Capital raised its target to $325, Wolfe Research to $375, and RBC Capital to $425, citing surging demand for custom AI chips and optical interconnect products. The move was also supported by bullish sentiment from Marvell's recent Investor Day, where management lifted guidance substantially.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Marvell's earnings are scheduled for December 1, 2026 (date not yet confirmed); consensus EPS estimate is $1.10.
Latest research
View all research →In-depth equity research from the BestStocks desk — earnings breakdowns, valuation deep dives, and sector analysis behind the changes we detect.
Stock AnalysisOctober 13, 2026 · 10 min read
Johnson & Johnson (JNJ) Falls ~6% Despite a Q3 Beat-and-Raise
Johnson & Johnson fell about 6% to roughly $247.63 on October 13 after third-quarter results — an unusually large move for a defensive Dow stalwart with a beta near 0.21. The strange part: at the headline it was a beat-and-raise. Adjusted earnings of $2.59 topped estimates and the company raised full-year guidance, lifting adjusted EPS to about $11.10 at the midpoint and putting sales on track to cross $100 billion for the first time. The stock fell anyway, and the main reason was the device business: MedTech sales of about $8.6 billion grew just 2.5% and missed Wall Street's estimate for a second straight quarter, against a strong 7.9% for the Innovative Medicine drug division. On top of that, the guidance raise was modest, the adjusted 'beat' was still down about 7.5% from a year earlier, and the stock had run up about 30% over the past year, leaving it priced for good news. A separate, largely accounting story grabbed headlines: reported GAAP net income collapsed to about $210 million (EPS of $0.09) on roughly $7.6 billion of special charges, about $5.5 billion of it a talc-litigation provision — but that settlement had been announced back in July, so the quarter merely booked the charge rather than breaking news. Pharma peers and the market barely moved, confirming a company-specific drop. The trailing P/E near 30 looks alarming but is distorted by the charges; on adjusted earnings the stock trades closer to 22 times forward. Analysts keep a Buy consensus with an average target near $280, above the price.
JNJRead →
Stock AnalysisOctober 12, 2026 · 10 min read
IonQ (IONQ) Falls ~9% on a $1.3B All-Stock Cybersecurity Acquisition
IonQ fell about 9% to roughly $36 on October 12 on a day it announced a definitive agreement to acquire Elisity, a zero-trust cybersecurity company, in an all-stock deal worth up to $1.3 billion. The counterintuitive part is the point: a stock dropping on its own acquisition. The all-stock structure is why — IonQ's share count is already up about 50% over the past year as it funds an acquisition-and-fundraising spree largely with stock, and Elisity is its third billion-dollar-scale deal in roughly 16 months, after the mostly-stock Oxford Ionics purchase and the cash-and-stock SkyWater acquisition. The strategic logic is forward-looking (pairing post-quantum cryptography with Elisity's zero-trust platform to sell 'quantum-era' security), but the market read the news as more dilution and more strategic sprawl from a pre-profit company valued near $14 billion on just $246 million of revenue — about 58 times sales, with an operating margin near negative 380%. A sign of company-specific pressure: IonQ fell about 9% while quantum peers Rigetti and D-Wave fell closer to 5.5% and the Nasdaq-100 slipped under 1% — more than the sector alone would explain. Wall Street stays overwhelmingly bullish on the long-term quantum roadmap — a Strong Buy consensus with an average target far above the price — which is exactly why a story stock like this swings so violently on news.
IONQRead →
Stock AnalysisOctober 12, 2026 · 10 min read
Manhattan Associates (MANH) Jumps ~6% on a Morgan Stanley Upgrade to Overweight
Manhattan Associates jumped about 5.5% to roughly $216 on October 12 — after running as high as about $221 — on a Morgan Stanley upgrade to Overweight from Equalweight and a price-target raise to $250 from $180. The move bucked a down software tape: supply-chain peers were flat and the software sector fell, marking this as an idiosyncratic, catalyst-driven move. Analyst Chris Quintero leaned on three points — accelerating cloud subscription bookings under CEO Eric Clark, a narrative shift from Manhattan being seen as AI-vulnerable to an AI beneficiary via its agentic-AI suite, and a more attractive valuation — while citing only about 1–2% upside to consensus revenue, a tell that this is a re-rating of sentiment as much as of the numbers. The business is a genuinely profitable, cash-generative franchise (56% gross margins, ~25% operating margins, a net-cash balance sheet, ~$400M of free cash flow, cloud revenue up in the mid-20s percent), but it is not cheap: near a 52-week high at ~62x trailing and ~37x forward earnings after a ~70% six-month run, the upgrade pushed it to within a few percent of the ~$228 average analyst target. The next hard test is third-quarter earnings on October 27.
MANHRead →
Stock AnalysisOctober 8, 2026 · 9 min read
Chipotle (CMG) Surges ~6% on a Report Starbucks Explored a Takeover
Chipotle jumped about 6% to roughly $32.54 on October 8 — after running as high as about $33.40 — on a Financial Times report that Starbucks has explored a potential takeover of the burrito chain. The key word is explored: the report describes preliminary, exploratory interest, not a formal offer, and neither company confirmed a deal, so this is a stock moving on takeover speculation that could reverse if the idea goes no further. The speculation still landed hard — volume ran about three times normal — because a Starbucks–Chipotle combination would be enormous (nearly $50 billion in combined sales, potentially the largest restaurant deal ever if completed) and would reunite Starbucks CEO Brian Niccol with the chain he ran from 2018 to 2024. It resonated partly because Chipotle had become cheap for Chipotle: down about 19% over the past year and trading below the ~$44 average analyst target even after the pop, a high-quality, cash-generative brand at a discount is exactly the profile that draws suitors. But skepticism is warranted: Starbucks fell about 3% on the prospect of a $45-billion-plus deal that would strain its balance sheet mid-turnaround, the strategic fit between coffee and fast-casual Mexican is debatable, and exploratory interest frequently never becomes an offer. The classic M&A-speculation cross-section — target up, acquirer down, McDonald's higher — tells the story; the next hard data is Chipotle's October 28 earnings.
CMGRead →
Stock AnalysisOctober 7, 2026 · 10 min read
NetApp (NTAP) Rises ~3.5% as Evercore Upgrades to a Street-High $300 on AI Storage
NetApp outperformed a weaker broader market on October 7, rising about 3.5% to roughly $236.50 after Evercore ISI's Amit Daryanani upgraded the stock from In Line to Outperform and set a Street-high $300 price target, up from $210. The move was less about one call than the cluster behind it: over roughly a week, Loop Capital went to $260, TD Cowen to $250, and Goldman to $240, and Evercore has now leapfrogged them all with a rating upgrade — a sell-side re-rating of NetApp as an AI-storage beneficiary, its all-flash arrays and ONTAP software positioned for the data pipelines that feed GPU clusters (a story reinforced by its late-September deal to buy PEAK:AIO and its Novus launch, both earlier developments rather than a fresh catalyst). NetApp rose even as long-dated Treasury yields hit their highest since 2002 in a rates- and oil-driven risk-off that pressured high-multiple shares. But the stock is not cheap: up roughly 96% over the past year, it trades near 23 times forward earnings and 6 times sales for a business growing revenue in the low-double-digits, so the upgrades are betting AI lifts both growth and the multiple. And the Street is genuinely split — the published average target near $206 sits below the price, reflecting both the lag before the newest hikes propagate and real disagreement: a camp of fresh below-price targets (Wedbush's Hold at $170, plus Citi, Barclays and Bank of America in the $190–$220 range) against the bulls at $240–$300. Without an unusually heavy-volume surge, this is a sell-side re-rating; the fundamentals arrive with December 1 earnings.
NTAPRead →
Stock AnalysisOctober 5, 2026 · 9 min read
Vaxcyte (PCVX) Surges ~35% as VAX-31 Meets All Primary Endpoints in Pivotal Phase 3 Trial
Vaxcyte surged to roughly $76 on October 5 — up about 35% after opening near $87 (about +54%) — when it reported positive topline data from OPUS-1, the pivotal adult Phase 3 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine. The trial met all of its prespecified primary endpoints on immune-response and safety measures: in adults 50 and older, VAX-31 met non-inferiority on all 20 serotypes it shares with Pfizer's Prevnar 20 and 17 of the 19 it shares with Merck's Capvaxive (the two exceptions cleared only a less-stringent historical bar), and superiority on the three serotypes unique to VAX-31, with safety similar to the incumbents. It is the profile a broader, 31-valent shot needs to take share in a multi-billion-dollar adult pneumococcal market — and the market priced it as a transfer of value, with Pfizer down about 1.6% and Merck about 3.4% while the biotech index was flat. Vaxcyte is still a clinical-stage, pre-revenue company — a roughly $1 billion annual loss, no P/E, and years from revenue, with two more Phase 3 trials due in 2027 and a planned filing in 2028 — but about $2.5 billion of cash and investments gives it runway, and sell-side targets sit well above the current price (Guggenheim raised its target to $125 the same day; Mizuho and Jefferies reiterated standing Buys at $163 and $146). The stock's gap-up-then-fade captures the tension between clearly good data and the execution still ahead.
PCVXRead →